Generic Medicine Info
Indications and Dosage
Acute exacerbations of chronic bronchitis
Adult: 300 mg bid. Max treatment duration: 10 days.
Renal Impairment
CrCl (mL/min) Dosage
<25 Contraindicated.
Hepatic Impairment
Mild to moderate: Max: 300 mg daily. Severe: Contraindicated.
Cap: May be taken with or without food.
Active peptic ulcer. Severe hepatic and renal impairment (CrCl <25 mL/min).
Special Precautions
Patient with history of peptic ulcer. Mild to moderate renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Epigastric pain, taste alteration, angioedema.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Cold, dyspnoea.
Skin and subcutaneous tissue disorders: Cutaneous hypersensitivity reactions (e.g. urticaria, erythema, eczema).
Description: Erdosteine, a prodrug of erdotin, inhibits bacterial adhesion to epithelial cells and opens disulphide bonds in the bronchial mucoproteins, thereby reducing the viscosity of mucus and purulent sputum.
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour.
Distribution: Distributed in the broncho alveolar lavage. Plasma protein binding: Approx 64.5%.
Metabolism: Undergoes first-pass metabolism to its active metabolite, N-thiodiglycolyl-homocysteine (M1).
Excretion: Mainly via urine, as metabolites. Elimination half-life: 1.46 hours (erdosteine); 1.62 hours (metabolite).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Erdosteine, CID=65632, (accessed on Jan. 22, 2020)

Store at 25°C.
ATC Classification
R05CB15 - erdosteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
Anon. Erdosteine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 14/08/2018.

Buckingham R (ed). Erdosteine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 14/08/2018.

Joint Formulary Committee. Erdosteine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 14/08/2018.

Disclaimer: This information is independently developed by MIMS based on Erdosteine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Edotin
  • Erdomex
  • Ertusin
  • Ethiros
  • Medistein
  • Mucotein
  • Muctrien
  • Recustein
  • Vestein
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in